{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010837","form_type":"8-K","ticker":"NDRA","cik":"0001681682","company_name":"ENDRA Life Sciences Inc.","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.095718+00:00","generated_at":"2026-05-31T08:51:20.407422+00:00","sec_items":["3.03","5.03","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ENDRA Life Sciences announces 1-for-50 reverse stock split to regain Nasdaq bid price compliance","bullets":["Reverse split effective Aug 20, 2024; shares outstanding drop from ~72.4M to ~1.4M.","Authorized shares reduced from 1B to 20M; fractional shares are rounded up to whole shares.","Split intended to raise bid price above $1.00 to meet Nasdaq continued listing requirement.","New CUSIP 29273B 401; common stock continues trading under NDRA on Nasdaq.","Board set ratio on Aug 8 after stockholder authorization at Aug 6 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010837","json":"https://secwatch.observer/filing/0001654954-24-010837.json","markdown":"https://secwatch.observer/filing/0001654954-24-010837.md","text":"https://secwatch.observer/filing/0001654954-24-010837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/0001654954-24-010837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1681682/000165495424010837/endra_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:51:20.407422+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}